Alan Shatter (Dublin South, Fine Gael)

Lariam is a chemo prophylactic agent first authorised for use in 1989 by the Irish Medicines Board which is the statutory body charged with regulating the use of medicines to ensure the quality, safety and efficacy of medicines available in Ireland. It remains the medication of choice for the Defence Forces for overseas missions to certain malarious areas. While certain risks associated with the use of the drug were highlighted in drug safety newsletters in 1996 and 2003, the Irish Medicines Board remained of the view that the benefit-risk profile for the product remained acceptable. The board continues to review the safety of this and all other medicines on an ongoing basis and updates the product information as appropriate.

In accordance with best practice in prescribing this medication - and taking account of the contra-indications, warnings and side effects highlighted by the Irish Medicines Board - the Defence Forces screen all personnel for medical suitability. The screening system rules out from overseas service personnel with certain conditions such as, for example, depression, anxiety, neurodegenerative disorders, etc., which, as has been indicated by the Irish Medicines Board, are more likely to precipitate serious adverse reactions to Lariam. Pregnant personnel are also excluded.

In the case of overseas missions to malarious areas, the medical screening involves an assessment of the individual's suitability to be prescribed the selected anti-malarial agent in line with current Irish Medical Board guidelines. This typically involves review of the individual's previous experience, if any, with the medication. His or her medical history is also screened for those conditions which have been identified as precipitating serious side effects in association with the medication. In addition, blood tests are carried out to ensure that the liver is healthy, as liver disease is an accepted contraindication to the use of Lariam.

It is the policy of the Defence Forces medical corps that personnel found suitable for Lariam should commence their medication three to four weeks in advance of their travel. The purpose of this precaution is twofold. While it allows a slow build-up of the medication in the bloodstream, it also permits assessment by the person of his or her individual reaction to the medication while still in Ireland. During this probationary period the individual can consult a medical officer over any adverse reaction, minor or major. Some minor reactions may be transient, but if persistent or troublesome, the individual will be deemed to have sensitivity to the medication and found not medically suitable for the mission.

Additional information not given on the floor of the House.

The Defence Forces take all necessary precautions in assessing the suitability of personnel before prescribing Lariam in accordance with the prescribing instructions and information provided by the Irish Medicines Board. Personnel are screened both before and after deployments and all necessary actions are taken to ensure those with contra-indications to Lariam use are deemed unsuitable for overseas service and not prescribed the medication.

There are three other anti-malaria medications available: Chloroquine, Malarone and Doxycycline. However, in the case of each of these products there are specific reasons they are not suitable for use by the Defence Forces in sub-Saharan Africa which I will now set out. Chloroquine is no longer in use because of the development of widespread resistance. Doxycycline has to be taken in the absence of dairy products and can produce sun-sensitivity skin rashes in some individuals. This is particularly significant when used in very sunny climes. For this reason, it is not recommended for first-line use by the Defence Forces in sub-Saharan Africa. Malarone is unsuitable for use as it is licensed by the Irish Medicines Board for no more than 28 days continuous use in a malarious area. In this context, this prophylactic agent is only suitable for use where the overseas deployment does not exceed 28 days.

These are among the reasons Lariam remains the anti-malaria chemoprophylactic agent of choice in areas where the predominant species of malaria is the virulent Plasmodium Falciparum. Lariam, therefore, is the agent of first choice on any sub-Saharan missions undertaken by the Defence Forces. On the other hand, Doxycycline is the anti-malaria chemoprophylactic agent of choice in Afghanistan where the predominant species of malaria is the less virulent Plasmodium Vivax.

See this speech in context